Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 51.55 EUR -0.39%
Market Cap: 10.6B EUR
Have any thoughts about
Recordati Industria Chimica e Farmaceutica SpA?
Write Note

Recordati Industria Chimica e Farmaceutica SpA
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Recordati Industria Chimica e Farmaceutica SpA
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Short-Term Debt
€50.3m
CAGR 3-Years
20%
CAGR 5-Years
25%
CAGR 10-Years
6%
Newron Pharmaceuticals SpA
SIX:NWRN
Short-Term Debt
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
Pierrel SpA
MIL:PRL
Short-Term Debt
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Friulchem SpA
MIL:FCM
Short-Term Debt
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shedir Pharma Srl Unipersonale
MIL:SHE
Short-Term Debt
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Market Cap
10.6B EUR
Industry
Pharmaceuticals

Recordati Industria Chimica e Farmaceutica SpA is a well-established pharmaceutical company based in Italy, renowned for its commitment to innovation and high-quality healthcare solutions. Founded in 1926, Recordati has evolved from a small family business into a global player in the pharmaceutical industry, focusing on the development and marketing of specialty pharmaceuticals, particularly for rare diseases and niche therapeutic areas. With a strategic emphasis on expanding its portfolio through research and development as well as targeted acquisitions, the company showcases a strong pipeline of products designed to address unmet medical needs, thus positioning itself as a crucial player in the evolving healthcare landscape. For investors, Recordati presents a compelling opportunity rooted in its steady growth trajectory and solid fiscal health. The company boasts a diverse revenue stream generated from its proprietary medicines, coupled with a robust international presence that spans over 150 countries. With ongoing efforts to strengthen its research capabilities and expand into emerging markets, Recordati is strategically positioned to capitalize on the rising global demand for specialized healthcare products. Its proven track record of performance, paired with a focus on sustainability and corporate responsibility, further enhances its attractiveness as a long-term investment, aligning well with the values of investors seeking ethical and financially sound opportunities in the pharmaceutical sector.

REC Intrinsic Value
53.15 EUR
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Recordati Industria Chimica e Farmaceutica SpA's Short-Term Debt?
Short-Term Debt
50.3m EUR

Based on the financial report for Jun 30, 2024, Recordati Industria Chimica e Farmaceutica SpA's Short-Term Debt amounts to 50.3m EUR.

What is Recordati Industria Chimica e Farmaceutica SpA's Short-Term Debt growth rate?
Short-Term Debt CAGR 10Y
6%

Over the last year, the Short-Term Debt growth was 216%. The average annual Short-Term Debt growth rates for Recordati Industria Chimica e Farmaceutica SpA have been 20% over the past three years , 25% over the past five years , and 6% over the past ten years .

Back to Top